This study aims to assess the efficacy and the cost of a French team work experiment between nurses and GPs for the managing of type 2 diabetes patients. Our study was based on a case control study design in which we compare the evolution of process (standard follow-up procedures) and final outcomes (glycemic control), and the evolution of cost. The study is realized for two consecutive periods between type 2 diabetes patients followed within the team work experiment (intervention group) or by "standard" GPs (controlled group).
Introduction
The improvement of the quality of care delivered by health professionals and the strengthening of primary care organization are seen as two key elements for increasing the performance of health care systems in a context of increasing demand and constraints in resources [1] [2] [3] [4] [5] [6] . Thus, numerous countries have undertaken reforms that aim at improving medical practices or organizing in a different way the provision of primary or ambulatory care and services, especially for chronic patients. This requires the production of medical practice guidelines and the implementation of "evidence based medicine" in daily practice through policy intervention close to doctors and the implementation of primary care and services organisational innovations: chronic care and/or disease management, performance based economic incentives, group practice and team work [7] .
Numerous systematic literature reviews are henceforth available [8] [9] [10] [11] [12] [13] [14] [15] . Passive intervention policy, which includes the simple provision of educational material and standard education activities (e.g. conferences, congresses,...) are considered to be little effective. On the contrary, more active policy interventions have proved to be more effective. These include more advanced continuing medical education strategies (e.g. academic detailing); therapeutic information systems, audit and feedback as well as electronic reminders; and finally, all "organisational-oriented" policies. Within the latter, our concern is specifically about policies focused on teamwork and cooperation between GPs and nurses, when nurses substitute or supplement physician workforce. Most of the studies converge in their conclusions: nurses adequately trained for specific actions (e.g. prevention, first contact, follow-up of a chronic patient…) can deliver care and services at least from a same level of outcome in terms of quality -indeed superior when the nurse act in complement -and with a greater level of outcome in terms of satisfaction, than of primary care doctors [10, 16, 17] . The magnitude of cost saving and of efficiency gains depends on salary and productivity differentials between nurses and GPs, and possible duplication.
In France, in spite of a public debate on the levers for performance improvement at the professional or organisational levels [18] [19] [20] [21] [22] , the recent reforms conserve an "embryonic character". Our health system still combines a relative free and comprehensive access to care and services for insured [23, 24] , with a weak regulation both of professional practices and ambulatory care organisations. One can observe that the French health care system has a fragmented ambulatory care system, more than a formal primary care organisation. Most of ambulatory care professionals are self-employed and work in solo practice paid on a fee-for-service basis. They are historically not subject to constraint by any strict mandatory quality regulation, and only recently both continuing medical education and the evaluation of professional practice have become mandatory.
As a consequence, several signs of inefficiency in health care delivery have come to light; especially for chronically ill patients for whom there has been no dramatic improvement in the care deliverye.g. for diabetes patients [25] [26] [27] [28] [29] -despite their growing place in the burden of disease and the fact that they currently consume an increasing share of the French health care system's resources [30, 31] .
After all, some experiments of networks, GP group practices, skill mix and teamwork (e.g. between GPs and nurses), are supported by an increasing number of stakeholders (sickness funds, state and local representatives…) and professionals' representatives [32, 33] . A national policy experiment in cooperation and skill mix was carried out between 2004 and 2008 [33, 34] . This policy authorized ten experiments which involved mainly the transfer of: technical procedures, follow-up of chronic patients with hepatitis, prevention. Only two of them are related to ambulatory care, and one to general practice: the ASALEE experiment (Action de Santé Libérale en Equipe 1 ).
Our general objective is to assess the efficacy and the cost of the ASALEE experiment regarding the management of type 2 diabetes patients, defined by the fact that they are treated by at least one oral anti-diabetic medication, which represents the bulk of the nurse working time Nurses are also involve in: counseling for high blood pressure, screening for cognitive problems and cardiovascular risk factors in individuals over 75 years old, screening campaigns (breast cancer, cervix cancer, cognitive disorder). Our specific objectives are: first, to assess the efficacy both regarding process (adequacy of follow-up procedures) and final (glycemic control) outcomes; second, to assess the difference of impact between two levels of nurse intervention in supplement to the GP: systematic electronic patient registry and electronic clinical reminder (level 1) combine or not with patient education and counselling (level 2); third, to assess the impact on direct costs for the National Health Insurance Funds, including additional cost generated by ASALEE experiment (i.e. nurses' wages,...).
Materials and methods
For type 2 diabetes patients, the activity provided by the nurses complements the GPs' at two levels. The first level (level 1) of intervention by the nurses is a systematic electronic patient registry of type 2 diabetes patients. This list was based on of the GPs' electronic patient records. For all these patients, the nurses log specific information (mainly requested biological results for the follow up). If require, the nurses can introduce electronic reminders inside electronic patient records. These electronic reminders alert the GP, during the patient's visit, the examinations to be conducted according to the national guidelines. The second level of intervention (level 2) is patient education and counselling in order to give nutritional-hygienic and treatment compliance advices. They are performed by nurses after a referral from the GP and are conditioned by an agreement from the patient.
Our evaluation design was constituted by three distinctive case control studies which compare the evolution of three dimensions of results between two consecutive periods between the intervention (ASALEE experiment) and the controlled groups (IGs vs. CGs). For the latter no nurses' assistance in their practice was developed. The three domains assessed were: efficacy regarding process outcomes, efficacy regarding final outcome, costs. Then, IGs cases were based on three subsamples of type 2 diabetes patients followed by GPs and nurses of the ASALEE experiment -depending on the level of nurses intervention they had benefitted -between June 2004 and May 2007 and still followed in May 2007 (intention to treat study). These three IG subsamples were compared, a posteriori, with those of three CGs. It should be noted that controlled group samples was matched to intervention group samples at baseline, with at least an equivalent distribution in terms of age and gender. Table 1 gives the distribution of all the variables for IGs compared with the distribution in the CGs; we could observe that characteristics of type 2 diabetes patients in the IGs and in the CGs are similar. Eligible Population * Due to technical consideration number of age classes were dependent on the nature of assessment ** Due to technical consideration number of waves classes were dependent on the nature of assessment
The first efficacy evaluation was based on the analysis of the evolution between two consecutive periods -between July 2005-June 2006 (t-1) and between July 2006-June 2007 (t) -, of process outcome measures, which corresponds to the probabilities of becoming or still be adequately followed-up, over one year, for six standard follow-up procedures recommended by the French National Authority in Health guidelines. According to these guidelines, the rate of HbA1c of patients suffering from diabetes must be controlled at least three times a year and they must also be subjected to a biological examination every year (creatinemia, microalbuminuria, lipid check-up), to an electrocardiogram or to a consultation with a cardiologist, and funduscopy. 838 type 2 diabetes patients in the intervention group were compared with those of 1018 type 2 diabetes patients in the controlled group (i.e. followed by standard GPs, without any nurse intervention in their practice). The ASALEE experiment is considered efficient if the proportion of patients that become or still be adequately followed-up over one year is greater than in the controlled group. We particularly look at the difference of impact between the two levels of nurse's intervention within the ASALEE experiment. 
We have used logistic regressions to model probabilities of becoming or still be followed correctly over one year for the six procedures (HbA1c, microalbuminuria, funduscopy, creatinemia, electrocardiogram, lipid check-up) and between the CG and the IG. For the patient in the latter we take in consideration whether or not the participants have had nurse visits for education and counselling. The results were controlled by: age (less than 49, from 50 to 59, from 60 to 69, from 70 to 79, over 80), gender (female or male), location within the Deux-Sèvres department (north, south), type of Mandatory Social Security Funds (salaried employees, farmer workers), the presence or not of medicated treatments indicating lipid problems and/or diabetes complications, the type of medicine treatment for diabetes (one oral antidiabetic drug, the association of two oral antidiabetic drugs, the association of oral antidiabetic drug and insulin).
The second efficacy evaluation was based on the analysis of the evolution over one year of the efficacy through final outcomes: the probabilities, before and after the intervention, of maintaining one's glycosylated haemoglobin 3 (HbA1c) or reducing it to a level below or equal to three different thresholds: 6.5%, 7%, 8%. Measuring HbA1c before and after the intervention of the nurses was performed for 588 patients of the ASALEE experiment. The evolution of HbA1c was compared to that of a control group of 202 type 2 diabetes patients followed by a panel of standard GPs (with no nurses intervention in their practices) 4 . The ASALEE experiment is considered efficient if the proportion of patients under glycemic control improve, over one year, greater than in the controlled group. We particularly look at the difference of impact between the two levels of nurse's intervention within the ASALEE experiment.
We used logistic regressions to model probabilities of maintaining or reducing HbA1c, before-andafter the intervention, regarding the three different thresholds of glycemic control and between the CG and the IG. For the latter we take in consideration whether or not the patients have had nurse visits for education and counselling. The results were controlled by: age (under 65, over 65), gender (woman versus man), the HbA1c status (value at baseline, number of HbA1c tests performed in the year following inclusion, number of months separating the measurements before-and-after) and seasonality (waves The costs analyses were based on claims data and we distinguished the total expenditure for all proceduresi.e. all the direct cost for type 2 diabetes patients (hospital and ambulatory care procedures where include) reimbursed by the National Health Insurance Funds -and total expenditure specific to type 2 diabetes. These latter included all the direct costs allocated to diabetes by using the coding of medical procedures and services stemming from claims data: all the expenses of following up diabetes, including those related to the risk factors of diabetes (e.g. visits or treatment for smoking cessation) and its complications (e.g. treatment for ischemic cardiopathy).
The evolution of theses costs were compared between the IG, 795 type 2 diabetes patients, and the CG, 956 type 2 diabetes patients followed by "standard" GPs (with no NURSES intervention in their practice). It should be noted first that the cost for ASALEE patients is increased by the expenses specific to the experiment (nurses' salaries, training expenses, etc.), i.e. €60/yr per patient.
We used a linear regression model in order to compute total and specific to diabetes costs in t according to the t-1 expenditures, between the IG and the CG and controlled by the following confounders: age (< 50 years old, 50-60 years old, 60-70 years old, 70-80 years old, > 80 years old), gender (woman or man), location within the department (north, south), type of Mandatory Social Security Scheme (salaried/employees or farmers people), the presence of treatment indicating lipid troubles and/or cardiovascular complications of diabetes (present or not), type of medicinal treatment 3 Glycosylated haemoglobin, glycated haemoglobin or more simply blood sugar provides the measurement of red blood cells fixing glucose in the haemoglobin of the organism. This concentration depends on cumulated variations of glycemia (rate of glucose in the blood) during the last 3-4 months. HbA1c expresses the glycemic control of a type 2 diabetes patient. This is why it is recommended to dose it every three months. In a non-diabetic individual, less than 6% of haemoglobin is glycated. for diabetes (one oral antidiabetic drug, the association of two oral antidiabetic drugs, the association of oral antidiabetic drug and insulin), hospitalization (at least one hospitalization in t-1, at least one hospitalization in t, at least one hospitalization in t and in t-1, none).
Results
Descriptive statistics show that type 2 diabetes patients included in the experiment ASALEE are significantly better followed than other control patients, for all the process outcomes retained at the two consecutive periods , and that the improvement between the two periods is greater for them (Cf. Table 2 ). Logistics models confirm this fact (see Table 3 ) and we therefore observe, ceteris paribus, that a type 2 diabetes patient followed up in the ASALEE experiment has, depending on procedures, 2.1 to 6.8 times more chances than one followed-up by another "standard" GP of remaining or becoming well followed-up over one year (OR equals 2.1 for HbA1c to 6.8 for microalbuminuria tests).
The fact that a type 2 diabetes patient within the IG benefits from a visit for education and counselling provided by nurses -44% of patients were concerned -does not increase dramatically these oddratios, even if they all increase except for carrying out creatinemia measurements (see Table 4 ). 
Ref.: modality of reference
With respect to the evolution of HbA1c value over one year, descriptive statistics and t-test (see Table  5 ) show that the type 2 diabetes patients enrolled in the ASALEE experiment, and who experienced a visit for education and counselling, had a statistically significant greater percentage point reduction in their HbA1c level (-0.34) than that of ASALEE patient without any nurses visits (-0.13) and of control group patients (-0.1). Notes: p value in bold are significant (p<10%)
The specific effect of the level 2 nurse intervention on the improvement of the glycemic control, within the ASALEE experiment and compared to the control group, is confirmed by the results of logistic models (see Table 6 ).
We observe that the probability of maintaining one's HbA1c or reducing it to 8% or less over one year is 1.8 times greater for the type 2 diabetes patients in the ASALEE group than for those in the control group (OR=1.8 for p<5%), ceteris paribus. Nevertheless, when seeking a more stringent judgement criterion, i.e. when the HbA1c threshold chosen is 6.5% or 7%, no significant differences were observed between the two groups.
That being said, when ASALEE patients are distinguished according to whether they were given at least one visit for education and counselling performed by nurses, there is a very significant improvement of glycemic control in the intervention group compared to the control group. We observed that the highest probability of having a HbA1c rate maintained at the same level or reduced to 8% or less over one year only significantly concerned patients who had had at least one therapeutic education (OR=2.7, p<1%). Moreover, the result is robust when applying a more stringent judgement criterion, i.e. an HbA1c threshold reduced to 6.5% or 7% (OR equal to 1.6 and 1.8 respectively with p≤5%). Ref.
: modality of reference
We estimated for type 2 diabetes patients total direct cost (e.g. for all procedures) and total direct cost specific to type 2 diabetes (e.g. only for procedures regarding type 2 diabetes, its risk factors and complications) between two consecutive periods: between July 2005-June 2006 (t-1) and between July 2006-June 2007 (t). It appears that the costs of ASALEE patients are equivalent to those of the patients of the controlled group for the two periods. For the total cost, they are respectively around 3.000 € in t and of 2.400 € in t-1.From the model we could conclude, ceteris paribus, in the absence of statistically significant difference in the progression of expenditure between patients followed up in ASALEE and patients of the control group. Finally, we have estimate the "theoretical" thresholds of additional cost from which we could consider that the differences in the progression of the expenditure would be significant between the ASALEE patients and those of the control group. From a step-bystep modelling and on the basis of our samples, we estimate these thresholds at 640 € for the total cost and at 470 € for the cost attributable to the diabetes, to its risk factors or to the complications. 
Discussion and conclusions
The main purpose of this study was to provide some empirical evidence about the efficacy and the efficiency of the French team work experiment ASALEE -mixing GPs and nurses skills -regarding the management of type 2 diabetes patients. More specifically, following a general design of a controlled before-and-after study, some logistic and linear models were estimated to assess: first, the efficacy according to process (adequacy of follow-up procedures) and final outcomes (glycemic control); second, the differential impact between two levels of nurses intervention in complement to the GP (systematic electronic patient registry and electronic clinical reminder with or without patient education and counselling); third, the impact on direct cost including additional cost generated by the experiment. 
With regard to the significant greater improvement, both of the follow-up adequacy and of the glycemic control, for the type 2 diabetes patients enrolled in the ASALEE experiment compared with those followed by "standard" GP practices, such an experiment could be considered as globally effective. In other words, the added value of teamwork between GPs and nurses is clearly demonstrated both for glycemic control (with the nurse visits for education and counselling) and process outcomes (with the nurse electronic patient registry and electronic GP reminder).
The improvement of the adequacy with guidelines regarding process outcome indicators calls for some comments. Firstly, it should be noticed that the positive impact on process outcome improvement for the follow-up of diabetes patients is in line with the results of the only evaluation of a French health care network yet published in France [35] . It is also in line with a great number of literature reviews [2, [8] [9] [10] [11] [12] 22, 37] with very similar design and method and for various quality improvement programs involving nurses (i.e. disease management, case management, team work or skill-mix experiment…). Secondly, in 2007, the level of adequacy with guidelines for process outcome in the ASALEE experiment were equivalent or not so far from those achieve in UK [37] and much greater than those observed by the French national survey on diabetes patients [28] for all the indicators except for carrying out eye examinations.
The positive results regarding our final outcome, the improvement of the HbA1c rate and then of the proportion of patients be under glycemic control, were rather innovative because the studies that assess this type of outcomes were in a much more restricted number. It has been shown that the rate of Hba1c significantly decreased over one year in the ASALEE experiment with a points percentage reduction of 0.2 for all patients included and of 0.34 for patients who had experienced the nurses visits for education and counselling. Then we observed an increase in the proportion of diabetes patients under glycemic control over a year significantly greater than in the control group.
This should be compared first to the secular trend affecting the HbA1c, and second to what it was observed in other studies. First, the experience of the UKPDS study demonstrated that the natural trend of HbA1c was to be worsened at a rate around 0.2% per year over a 10-year cohort observation period [38] . Second, the relative decrease in HbA1c here are consistent with the results of other studies with a very similar design and method and for various quality improvement programs: most of the studies observed a rather significant reduction of the Hba1c level, comprised between a 0.4 and a 1.0 point percent reduction, and then an increase in the proportion of diabetes patients under glycemic control [36] [37] [38] [39] [40] [41] [42] [43] [44] .
None of these studies concerned French experiments, and it is only recently that a disease management program lead by the National Health Insurance Fund for salaried people has been experimentally implemented for a targeted population of 140,000 diabetic patients. It is called SOPHIA and the results of its evaluation for final outcomes should not be available before mid-2010 5 .
A final set of results concerns the progression of costs over one year. These are not significantly higher in the ASALEE experiment than in the control group even if we take into account the additional cost generated by the experiment (i.e. nurses' wages,…): €60/yr per patient. These additional costs was estimated by ASALEE on the basis of its accounts and its own records of nurse working time dedicated to the follow-up of diabetes patients. They should be compared to the one estimated by the National Health Insurance Fund for employee for the SOPHIA experimental disease management on a routine basis: €120/yr per patient. Moreover, as has been shown by the sensitive analysis, this is still the truth even if we let up the hypotheses for the additional costs in the ASALEE experiment and if we reached them to a very high threshold (€640/yr per patient for the total cost and €470/yr per patient for the cost attributable to the follow-up or treatment of diabetes, its risk factors or its complications).
It should be mentioned that expenditure over one year is less here than that estimated by the French National Health insurance Fund for types 1 and 2 diabetes patients in long-term disease [25, 30] . This difference can mainly be explained by the fact that our sample is made up in the same way and that it is limited to patients covered by health insurance in the Deux-Sèvres department. It does not represent diabetic patients with complications leading to high expenses (e.g. diabetes patients under dialysis). Furthermore, it was not possible to take public hospital expenses fully into account. The -14 -exhaustiveness of the collection is better in t than in t-1, explaining part of the increase in expenditure between the two periods.
Nonetheless, our results are consistent with the results of existing studies in other countries in terms of cost progression, relatively moderate, on a short-term basis when a quality improvement program for chronic disease was implemented [13, 14, 40, 45] . The progression is due to the fact that the costs saving are expected in long term schedule. The progression is moderate because marginal cost of the procedures that should be run in order to ensure a better follow-up are very low regarding the total expenditure of diabetes patient.
Finally, the model of GP nurse cooperation developed within the ASALEE natural experiment can be considered as efficient. This evaluation contribute to the large national policy experiment of skill mixing which gives place to a series of works, namely a recent national recommendation by the French National Authority in Health ( Some limitations should be taken into account in our study. Firstly, there is no random selection of GPs, nurses and patients and then some selection bias could occur. Secondly, we have a case study design extended to a controlled before-and-after design only for the evaluation of the final outcome but not for the evaluation of process outcomes and cost. Nevertheless, for the latter, we are able to implement a clear controlled before-and-after design, but only for a subsample of type 2 diabetes patient within the ASALEE experiment, those who were included during the final wave of the experiment (respectively 382 and 356 patients). We have run these models and the results still are robust for these subsamples. Thirdly, our patient attrition rate -mainly due to a change of location or because of a death -was about 13%. Fourthly, the evaluation was restricted to a proportion of all the eligible ASALEE patients: 40% for the glycemic control, 47% for the process outcomes and 49% for the costs. Fifthly, we could not include in our analysis some important unavailable variables: clinical and socioeconomic status variables with a broader scope than for those available here (e.g. occupation, income, education); other final outcome (e.g. body mass index, microvascular and macrovascular complications, quality of life). Finally, the conclusions in terms of efficiency are not based on a joint analysis of effectiveness and cost at the individual level and the observation length is limited.
